FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Ariz. Admin. Code R4-23-607(A) says a person that is not an Arizona resident may not sell or distribute any controlled substance or prescription-only drug or device into Arizona without both a current Board-issued nonresident permit (pharmacy, manufacturer or wholesale) and the equivalent license from its home state. A.R.S. §32-1929(D) requires a Board application for a pharmacy outside the state that will dispense, sell or distribute drugs into Arizona, and the application must name the individual responsible to the Board. Under R4-23-607(E)(1), a nonresident pharmacy may sell prescription drugs in Arizona only to Board-permitted pharmacies, manufacturers or wholesalers, to Arizona-licensed medical practitioners, or to Arizona residents with a valid prescription. The rule text reviewed has no Arizona-licensed pharmacist-in-charge requirement, no separate nonresident sterile-compounding permit and no inspection-report requirement. The Arizona State Board of Pharmacy enforces these rules.

R4-23-607 was last amended effective 2020-03-14 (26 A.A.R. 223), and the Cornell copy shows it as current on 2026-09-23. The Board's own site (pharmacy.az.gov) blocked automated access with bot protection, so its current application checklist was not checked. It is not confirmed whether the Board asks nonresident applicants for an inspection report; check with the Board. Harbor Compliance (secondary) lists the application documents as a home-state permit copy, a list of officers and any disciplinary orders, with a $480 biennial fee. Pending or changing items: Arizona HB4036 (2026), titled "bulk drug substances; prohibitions", would have restricted compounding of certain weight-management drugs and added bulk-ingredient quality rules with $1,000-per-dose penalties (House summary dated 2026-02-13: https://www.azleg.gov/legtext/57leg/2R/summary/H.HB4036_021326_IT.DOCX.htm). Secondary sources (Frier Levitt; medspastandards.com, 2026-05-23) report it was withdrawn from committee on 2026-02-18.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

A.R.S. §32-1901 defines compounding to include preparing drugs 'for administration by a medical practitioner to the medical practitioner's patient and not for sale or dispensing.' The same definition excludes preparing drugs for sale to pharmacies, practitioners or other entities for dispensing or distribution, and copying commercially available products from bulk. Ariz. Admin. Code R4-23-410(B)(3) bars providing compounded products to anyone for dispensing or distribution. The exception is a product given to a medical practitioner to administer to their own patient, with each container accompanied by the written list required by R4-23-410(I)(5). The label must show the pharmacy's name, address and phone number, the product name, lot number and beyond-use date, and the statements 'Not For Dispensing' and 'For Office or Hospital Administration Only.' The rule sets no numeric quantity cap, but anticipatory batches require a history of valid prescriptions. R4-23-607(E)(1) lets a permitted nonresident pharmacy sell prescription drugs to Arizona-licensed medical practitioners, so the rules do not on their face bar nonresident office-use shipments. FDA's position is that 503A compounding needs patient-specific prescriptions, so this state allowance goes further than the federal view.

R4-23-410 was last amended effective 2006-12-04 (12 A.A.R. 3981). Cornell shows it as current on 2026-09-23, but it is older than two years and possibly stale if the Board has adopted newer USP-based compounding rules; check with the Board. It is not confirmed whether the Board applies R4-23-410 labeling to nonresident pharmacies. The Board website blocked automated access. AZ HB4036 (2026), "bulk drug substances; prohibitions", was reported withdrawn from committee on 2026-02-18 (secondary sources); see nonresident_pharmacy AZ notes.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Ariz. Admin. Code R4-23-607(A) bars any nonresident from selling or distributing prescription-only drugs into Arizona without a current Board-issued nonresident pharmacy, manufacturer or wholesale permit plus its home-state license. A.R.S. §32-1901 defines 'manufacturer' to include anyone who compounds or processes any drug 'in a place, other than a pharmacy.' The permit types in A.R.S. §32-1930(A) do not include a separate 'outsourcing facility' permit. A 2025 industry guide (secondary) says the Arizona Board licenses 503B facilities as drug manufacturers. Nonresident applicants submit a home-state permit, a drug or device list and their FDA registration. The Arizona State Board of Pharmacy enforces these rules.

The requirement that a nonresident permit is needed comes from primary sources (R4-23-607(A)). That 503Bs specifically get the nonresident manufacturer permit comes from a secondary source (ProRx eGuide, Dec 2025), which cites the Board's manufacturer-permit page. That page (pharmacy.az.gov/manufacturer-permit-information) blocked automated access and could not be checked. Harbor Compliance lists the Arizona manufacturer permit fee as $1,000, renewed every two years. An in-state representative or recent FDA inspection requirement for nonresident 503Bs was not confirmed.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Arizona is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

A.R.S. 36-2522(A) requires every person who prescribes, dispenses or administers controlled substances in Arizona to first hold a current license as a medical practitioner and be a registrant under the federal Controlled Substances Act - there is no separate state CS certificate. Separately, an MD who dispenses drugs kept in the office (take-home, not samples) must register with the Arizona Medical Board to dispense, pay the registration fee, and follow labeling, locked-storage and inventory rules (A.R.S. 32-1491(A)); MDs may not dispense Schedule II opioids except implantable devices or medication-assisted treatment (32-1491(B)). Dispensing without board registration carries a civil penalty of $300-$1,000 per transaction.

The dispensing registration is a general drug-dispensing registration with the licensing board, not a controlled-substance registration; DOs, NPs and PAs have parallel dispensing rules under their own boards (not verified here). Arizona also requires CSPMP registration for DEA holders (not opened in this session).

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Before prescribing an opioid analgesic or benzodiazepine listed in Schedule II, III or IV, a medical practitioner must obtain a 12-month patient utilization report from the Controlled Substances Prescription Monitoring Program, before the prescription and before any subsequent refill. Exemptions: hospice or palliative care; cancer or dialysis patients; when the practitioner will administer the drug; inpatient or residential treatment in hospitals, nursing, assisted living, correctional or mental health facilities; and up to a 5-day supply for an invasive/painful procedure or for an acute injury diagnosed in an emergency department. Separately, pharmacists must check before dispensing a Schedule II drug. Administered by the Arizona State Board of Pharmacy; each practitioner board enforces for its licensees.

Testosterone (C-III, not an opioid or benzodiazepine) is not caught. 36-2606(H) requires EHR vendors serving Arizona practitioners to integrate with the PDMP on or before December 31, 2026. PDMP TTAC also lists board rules and 32-1961.01 etc. (not reviewed).

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

A.R.S. 32-1491 lets a doctor of medicine dispense drugs and devices if the doctor registers with the board and pays the fee, labels each package (doctor, date, patient, drug, strength, directions), records the drug and reason in the chart, and keeps drugs locked with an ongoing inventory. Before dispensing, the doctor must give the patient a prescription and say it may be filled by the doctor or any pharmacy. Dispensing is limited to the doctor's own patients for conditions the doctor is treating, with direct supervision of staff. Schedule II opioids may not be dispensed (except implantable devices and MAT). Dispensing without registration carries civil penalties of $300 to $1,000 per transaction.

Section applies to MDs (Arizona Medical Board). DOs dispense under a parallel osteopathic provision not reviewed here.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

A clinician not licensed in Arizona may treat Arizona patients by telehealth after registering with the matching Arizona board (proof of an unrestricted license elsewhere, malpractice coverage, a statutory agent, a fee, annual updates) and must register with the Arizona PMP before prescribing controlled substances; registrants may not open an Arizona office or see patients in person (A.R.S. 36-3606). Boards may not require an in-person exam before prescribing except for Schedule II drugs, which need an in-person or audio-visual exam (A.R.S. 36-3602). Testosterone (C-III) has no Arizona-specific telehealth limit beyond general law. IMLC: member.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Nevada's 2025 aesthetic practice decision cites an Arizona State Board of Nursing advisory opinion titled 'Medical Aesthetic Procedures Performed by Licensed Nurses, Licensed Cosmetologist, Licensed Aesthetician and Certified Laser Technologists' (3-2021), and Nebraska's 2021 opinion says it adapted Arizona's procedure classification. The Arizona Board of Nursing and Arizona Medical Board websites returned HTTP 403 to automated requests on 2026-09-23, so the opinion's terms were not read. Separately, A.R.S. §32-1456 lets medical assistants administer injections only under the direct supervision of an MD, PA or NP.

Check the Arizona State Board of Nursing advisory opinions page (azbn.gov) directly; it could not be fetched automatically.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Wisconsin's 2025 IV guidance and Oregon's 2024 IV statement both cite the Arizona State Board of Nursing 'Advisory Opinion: Intravenous Hydration and Other Therapies' (revised May 2024). The document could not be read because the Arizona Board of Nursing site returned HTTP 403 to automated requests on 2026-09-23.

The AZBN opinion was published at azbn.gov/sites/default/files/AO-IV-Hydration-Other-Therapies.pdf according to the Wisconsin document; check it directly.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Arizona as 'Strict (Common Law)', citing Funk Jewelry Co. v. State (1935) and State ex rel. Board of Optometry v. Sears Roebuck & Co. (1967); MedPath Compliance (reviewed 2026-06-20) also lists Arizona as 'Yes' based on case law. Other med spa guides describe Arizona ownership as more permissive, particularly for NPs with full practice authority, so the doctrine's current reach is debated.

The cited cases concern optometry/jewelry businesses; Arizona's modern enforcement against med spa lay ownership was not confirmed.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

A.A.C. R9-7-1438 (amended effective 2024-01-04) lets health professionals (physicians, NPs, PAs meeting licensing requirements) perform laser and IPL cosmetic procedures. Laser technicians must complete 24 hours of didactic training, pass a department-approved exam (80% minimum), complete at least 24 hours of hands-on training with at least 10 supervised procedures per procedure type, and be certified; they may perform hair removal under indirect supervision (physician/NP need not be on site) and other cosmetic procedures (skin rejuvenation, vascular, tattoo removal, etc.) under direct supervision (physician/NP physically present). Supervising professionals must observe each technician at least every six months and keep records for three years. Lasers are registered with ADHS radiation regulation (A.A.C. Title 9, Ch. 7, Art. 14).

Whether RNs need technician certification was not confirmed from the fetched summary.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

A 2021 law-firm review cites A.R.S. §36-462 for the point that Arizona requires only a CLIA certificate. The Arizona Department of Health Services' Office of Laboratory Licensing and Certification is the state's CLIA agency. Arizona separately guarantees consumer direct-access testing (see that topic).

Source is from 2021 (older than 2 years), so it may be stale; confirm with ADHS (CLIAAZ@AZDHS.GOV).

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

A.R.S. §36-468 provides that a person 'may obtain any laboratory test from a licensed clinical laboratory on a direct access basis without a health care provider's request or written authorization' if the lab offers that test to the public on that basis. The lab must give the report to the person tested, stating in bold that the person is responsible for consulting their own provider. Labs may not bill insurers for direct-access tests, and providers have no duty to act on results they did not order.

Arizona's law has been in effect for about a decade (KJZZ, 2025).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Arizona is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Pending/failed: SB 1214 (2026), the 'Arizona Stem Cell and Regenerative Therapy Act', passed both chambers but was vetoed by Gov. Hobbs on June 19, 2026. The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Arizona does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.